Tumor immune microenvironment (TIME) consists of intra-tumor immunological components
and plays a significant role in tumor initiation, progression, metastasis, and response to …

Progress in sequencing technologies and clinical experiments has revolutionized
immunotherapy on solid and hematologic malignancies. However, the benefits of …

The field of oncology has been transformed by immune checkpoint inhibitors (ICI) and other
immune-based agents; however, many patients do not receive a durable benefit. While …

Tumor tissue engineering holds great promise for replicating the physiological and
behavioral characteristics of tumors in vitro. Advances in this field have led to new …

The heterogeneity of macrophages influences the response to immune checkpoint inhibitor
(ICI) therapy. However, few studies explore the impact of APOE+ macrophages on ICI …

Hepatocellular Carcinoma (HCC) remains a leading cause of cancer deaths. Despite the
rise of immunotherapies, many HCC patients don't benefit. There's a clear need for …

The majority of compounds designed against cancer drug targets do not progress to become
approved drugs, mainly due to lack of efficacy and/or unmanageable toxicity. Robust target …

The emergence of immunotherapy has dramatically changed the cancer treatment paradigm
and generated tremendous promise in precision medicine. However, cancer immunotherapy …

Hepatocellular carcinoma (HCC) is a high-incidence, poor-prognosis malignancy
worldwide, requiring new strategies for treatment. Ubiquitination, especially ubiquitination …

Hepatocellular carcinoma (HCC) exhibits high incidence and mortality rates in China. Most
cases are often diagnosed at late stages and require multi-strategy therapies. In recent …